SC 13G: Galera Therapeutics, Inc.

AI Summary

SC 13G filing by Galera Therapeutics, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — f Class of Securities: Common Shares, $0.001 par value per share (e) CUSIP Number:

Filing Documents

• alpi_sc13g.htm (SC 13G) — 28KB
• 0001376474-24-000167.txt ( ) — 29KB

Ownership

Item 4. Ownership See Items 5-9 and 11 of the cover page for each Filer. The sum totals for all filers are as below. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2,750,000 (b) Percent of class: 5.056% (c) Number of shares as to which the person has: 3 (i) Sole power to vote or to direct the vote: 2,750,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 2,750,000 (iv) Shared power to dispose or to direct the disposition of: 0 4

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 5

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: April 15, 2024 By: /s/ R Sofer C/O ALPHA PHARMA INVESTMENTS 6

View Full Filing

View this SC 13G filing on SEC EDGAR